Wave Life Sciences (NASDAQ:WVE) had its target price trimmed by Leerink Swann from $64.00 to $62.00 in a research report report published on Tuesday morning. The brokerage currently has an outperform rating on the stock. Leerink Swann also issued estimates for Wave Life Sciences’ Q1 2018 earnings at ($0.86) EPS, Q2 2018 earnings at ($0.89) EPS, Q3 2018 earnings at ($0.92) EPS, Q4 2018 earnings at ($0.95) EPS, FY2018 earnings at ($3.62) EPS, Q1 2019 earnings at ($0.62) EPS, Q2 2019 earnings at ($0.65) EPS, Q3 2019 earnings at ($0.68) EPS, Q4 2019 earnings at ($0.72) EPS, FY2019 earnings at ($2.79) EPS, FY2020 earnings at ($2.28) EPS and FY2021 earnings at ($5.94) EPS.
Other research analysts have also recently issued research reports about the stock. Zacks Investment Research cut shares of Wave Life Sciences from a hold rating to a sell rating in a report on Saturday, January 13th. BidaskClub upgraded shares of Wave Life Sciences from a hold rating to a buy rating in a report on Tuesday, February 13th. SunTrust Banks upped their price target on shares of Wave Life Sciences to $60.00 and gave the company a buy rating in a report on Friday, March 9th. Mizuho set a $34.00 price target on shares of Wave Life Sciences and gave the company a buy rating in a report on Tuesday, February 20th. Finally, TheStreet upgraded shares of Wave Life Sciences from a d+ rating to a c- rating in a report on Friday, January 5th. Two analysts have rated the stock with a sell rating and seven have given a buy rating to the stock. The company presently has a consensus rating of Buy and an average target price of $47.20.
Shares of Wave Life Sciences (WVE) opened at $41.50 on Tuesday. Wave Life Sciences has a 12 month low of $15.15 and a 12 month high of $55.95. The company has a quick ratio of 11.50, a current ratio of 7.67 and a debt-to-equity ratio of 0.02. The company has a market cap of $1,120.00 and a P/E ratio of -10.81.
A number of institutional investors and hedge funds have recently made changes to their positions in WVE. Point72 Asset Management L.P. acquired a new position in Wave Life Sciences during the third quarter worth $13,679,000. BlackRock Inc. boosted its holdings in Wave Life Sciences by 60.0% during the fourth quarter. BlackRock Inc. now owns 934,733 shares of the company’s stock worth $32,810,000 after purchasing an additional 350,570 shares during the last quarter. JPMorgan Chase & Co. acquired a new position in Wave Life Sciences during the third quarter worth $2,634,000. Artal Group S.A. acquired a new position in Wave Life Sciences during the fourth quarter worth $3,232,000. Finally, Bailard Inc. acquired a new position in Wave Life Sciences during the fourth quarter worth $2,773,000. Institutional investors and hedge funds own 79.66% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Wave Life Sciences (WVE) Price Target Cut to $62.00 by Analysts at Leerink Swann” was first reported by Chaffey Breeze and is owned by of Chaffey Breeze. If you are accessing this story on another domain, it was illegally stolen and reposted in violation of US and international trademark and copyright laws. The legal version of this story can be read at https://www.chaffeybreeze.com/2018/03/17/wave-life-sciences-wve-price-target-cut-to-62-00-by-analysts-at-leerink-swann.html.
Wave Life Sciences Company Profile
WAVE Life Sciences Ltd. is a genetic medicines company. The Company, through its synthetic chemistry drug development platform, designs, develops and commercializes a pipeline of nucleic acid therapeutic candidates for genetically defined diseases. The Company is engaged in developing oligonucleotides that target genetic defects to either reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins.
Receive News & Ratings for Wave Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Wave Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.